10:12 AM

Managing Diabetes Medications During Ramadan: A Clinical Guide to Preventing Hypoglycemia

Dr Neeraj Manikath, Claude.ai

Abstract

Ramadan fasting presents unique challenges for diabetes management, with hypoglycemia being the most feared acute complication. Approximately 1.5 billion Muslims worldwide observe Ramadan annually, including an estimated 50 million with diabetes. This review provides evidence-based strategies for medication adjustment during Ramadan fasting, emphasizing practical bedside approaches to minimize hypoglycemic risk while maintaining glycemic control. We discuss the pathophysiology of fasting-induced metabolic changes, risk stratification frameworks, drug-specific modifications, and clinical pearls derived from contemporary trials and real-world practice.

Introduction

The month of Ramadan requires Muslims to abstain from food and drink from dawn (Fajr) to sunset (Maghrib), with fasting duration varying from 11 to 20 hours depending on geographical location and season. Despite religious exemptions for those with serious illness, most Muslim patients with diabetes choose to fast[1]. The EPIDIAR study demonstrated that 43% of type 1 and 79% of type 2 diabetes patients fasted during Ramadan, with a 7.5-fold increase in severe hypoglycemia among type 1 diabetes patients[2].

The clinical challenge lies in restructuring medication regimens to accommodate the reversed circadian pattern of food intake, where two main meals (Suhoor before dawn and Iftar at sunset) replace the conventional three-meal pattern. This review synthesizes current evidence and clinical experience to provide actionable strategies for safe diabetes management during Ramadan.

Pathophysiology of Fasting in Diabetes

Metabolic Adaptations

During prolonged fasting, healthy individuals transition from glucose to fat oxidation within 12-16 hours, with hepatic glycogenolysis maintaining euglycemia for the first 24 hours, followed by gluconeogenesis and ketogenesis[3]. However, patients with diabetes experience dysregulated counter-regulatory responses.

Clinical Pearl: The "metabolic inflection point" typically occurs 8-10 hours into fasting in patients taking insulin or sulfonylureas, when hepatic glucose output cannot compensate for declining plasma glucose, particularly if pre-dawn medication doses are excessive.

In type 2 diabetes, endogenous insulin secretion (whether from residual beta-cell function or sulfonylurea stimulation) continues despite falling glucose levels, creating hypoglycemic vulnerability. Conversely, inadequate insulin during the post-Iftar period—when traditional high-glycemic foods are consumed—leads to hyperglycemic excursions.

The Biphasic Risk Pattern

Oyster to Remember: Hypoglycemia risk follows a bimodal distribution during Ramadan:

First peak: Mid-afternoon (2-5 PM), when fasting duration peaks and physical activity may increase before Iftar
Second peak: Late night/early morning (2-4 AM), particularly in patients who administer evening insulin after Iftar

Understanding this pattern informs both medication timing and patient education about symptom recognition.

Risk Stratification: The Foundation of Safe Management

The International Diabetes Federation (IDF) and Diabetes and Ramadan (DAR) International Alliance have established comprehensive risk categorization[4]. However, bedside application requires nuanced assessment.

High-Risk Category (Intensive Counseling Required)

Well-controlled type 1 diabetes
Type 2 diabetes on multiple insulin injections
HbA1c >8.5% despite oral therapy
CKD stage 3 (eGFR 30-60 mL/min/1.73m²)
Patients performing intense physical labor

Moderate to Low Risk

Well-controlled type 2 diabetes on lifestyle modifications, metformin, SGLT2 inhibitors, GLP-1 agonists, or DPP-4 inhibitors

Clinical Hack: Create a "Ramadan Risk Score" card for each patient during pre-Ramadan counseling (ideally 6-8 weeks before), documenting risk category and specific action plans. This serves as a quick reference for emergency room physicians and covering colleagues unfamiliar with the patient.

Medication-Specific Adjustments: The Art and Science

Metformin: The Safest Cornerstone

Metformin monotherapy carries minimal hypoglycemia risk and requires only temporal redistribution rather than dose adjustment.

Recommended Adjustment:

Once-daily formulation: Take with Iftar meal
Twice-daily: Larger dose with Iftar, smaller dose with Suhoor (e.g., 1000 mg + 500 mg)
Extended-release formulations: Preferentially use and administer with Iftar

Evidence: The CRATOS study showed no increase in hypoglycemia with metformin during Ramadan, with slight improvements in fasting glucose[5].

Clinical Pearl: For patients on 850 mg twice daily, consider switching to 1000 mg + 500 mg split rather than equal dosing. The larger evening dose addresses post-Iftar hyperglycemia without increasing daytime hypoglycemia risk.

Sulfonylureas: The Highest-Risk Oral Agents

Sulfonylureas pose significant hypoglycemia risk due to insulin-independent glucose-stimulated insulin secretion. The VIRTUE study demonstrated 5-fold higher hypoglycemia rates compared to DPP-4 inhibitors during Ramadan[6].

Recommended Strategy:

First choice: Switch to DPP-4 inhibitor or GLP-1 agonist 4-6 weeks before Ramadan
If continuation necessary:
- Reduce total daily dose by 30-50%
- Shift larger dose to Iftar, smaller to Suhoor
- Consider short-acting agents (gliclazide) over long-acting (glimepiride, glibenclamide)

Specific Adjustments:

Glimepiride 4 mg once daily → 2 mg with Iftar only
Gliclazide 60 mg twice daily → 60 mg with Iftar, 30 mg with Suhoor (or discontinue Suhoor dose)
Glibenclamide: Strongly avoid during Ramadan due to prolonged duration and high hypoglycemia risk

Oyster: The "Suhoor sulfonylurea paradox"—giving sulfonylureas at Suhoor seems logical to prevent fasting hypoglycemia, but peak insulin secretion occurs 4-6 hours post-dose, creating maximum hypoglycemia risk during mid-afternoon when no food intake is possible. This counterintuitive timing is a common error.

Clinical Hack: If patients insist on continuing sulfonylureas, provide a "hypoglycemia action card" with specific glucose thresholds for breaking fast (<70 mg/dL or 3.9 mmol/L, or <90 mg/dL if symptomatic), with instructions in local language and religious approval obtained from local scholars.

DPP-4 Inhibitors: The Ramadan-Friendly Choice

DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin, linagliptin) enhance glucose-dependent insulin secretion and suppress glucagon in a glucose-dependent manner, making them ideal for Ramadan.

Recommended Adjustment:

No dose reduction required
Continue same schedule: morning dose becomes Suhoor dose, evening dose becomes Iftar dose
Particularly suitable for replacing sulfonylureas

Evidence: The STEADFAST study showed vildagliptin had significantly lower hypoglycemia rates (3.0%) compared to sulfonylureas (7.4%) during Ramadan[7].

Clinical Pearl: When converting from sulfonylurea to DPP-4 inhibitor before Ramadan, allow 2-week overlap to prevent rebound hyperglycemia. Start DPP-4 inhibitor while reducing sulfonylurea dose by 50%, then discontinue sulfonylurea after 1-2 weeks.

SGLT2 Inhibitors: Effective but Requires Vigilance

SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin) promote glucosuria independent of insulin, providing glycemic control without direct hypoglycemia risk. However, dehydration and diabetic ketoacidosis (DKA) concerns arise during fasting.

Recommended Approach:

Continue at same dose
Administer with Suhoor meal to maximize hydration period
Crucial: Intensive counseling about adequate fluid intake between Iftar and Suhoor (minimum 2-3 liters)
Hold if patient develops vomiting, diarrhea, or decreased oral intake

Contraindications During Ramadan:

eGFR <45 mL/min/1.73m²
History of DKA
Patients unable to maintain adequate hydration

Evidence: SOAR study demonstrated safety of SGLT2 inhibitors during Ramadan with no increase in DKA when proper precautions observed[8].

Clinical Hack: Create a "hydration schedule" for patients on SGLT2 inhibitors: 500 mL water at Iftar, 500 mL at 9 PM, 500 mL at midnight, 500 mL at Suhoor. Use phone reminders or hydration tracking apps.

Oyster: The "euglycemic DKA trap"—patients on SGLT2 inhibitors can develop DKA with relatively normal glucose levels (200-300 mg/dL). Educate patients to seek medical attention for nausea, vomiting, or abdominal pain even if capillary glucose isn't severely elevated.

GLP-1 Receptor Agonists: Optimal Choice for Obese Patients

GLP-1 agonists (liraglutide, semaglutide, dulaglutide, exenatide) enhance glucose-dependent insulin secretion, suppress glucagon, delay gastric emptying, and promote satiety—all beneficial during Ramadan.

Recommended Adjustment:

Once-weekly agents (semaglutide, dulaglutide): Continue same schedule, no adjustment needed
Once-daily agents (liraglutide): Continue same dose, administer with Iftar or Suhoor consistently
Twice-daily agents (exenatide): Give within 60 minutes of Iftar and Suhoor

Evidence: LIRA-Ramadan study showed significantly lower hypoglycemia (1.1%) compared to sulfonylureas during Ramadan with superior weight control[9].

Clinical Pearl: For treatment-naïve patients, consider initiating GLP-1 agonists 8-10 weeks before Ramadan to complete dose titration and allow GI side effects to resolve before fasting begins.

Nausea Management Hack: If persistent nausea at Suhoor threatens fasting completion, try these strategies:

Administer GLP-1 agonist with Iftar instead of Suhoor
Consume bland, protein-rich Suhoor (eggs, cheese) rather than high-fat or sweet foods
Temporary dose reduction (e.g., liraglutide 1.2 mg instead of 1.8 mg) during Ramadan

Thiazolidinediones: Low Risk but Limited Use

Pioglitazone carries minimal hypoglycemia risk but has fallen out of favor due to weight gain, fluid retention, and cardiovascular concerns.

If Continued:

No dose adjustment required
Monitor for peripheral edema exacerbated by fluid intake patterns
Consider holding in patients with heart failure

Basal Insulin: Precision Timing is Everything

Basal insulin analogs (glargine, detemir, degludec) provide foundational glucose control but require careful adjustment.

General Principles:

Reduce total daily dose by 15-30% initially
Ultra-long-acting insulins (degludec, glargine U-300) provide more stable coverage with less hypoglycemia risk

Specific Regimens:

Once-Daily Basal Insulin:

Before Ramadan: Evening administration
During Ramadan: Switch to Iftar time, reduce dose by 20%
Alternative: Split into twice-daily at 60% dose with Iftar, 40% dose with Suhoor

Twice-Daily Basal Insulin:

Pre-dawn dose: Reduce by 30-50%
Evening (Iftar) dose: Reduce by 10-20%
Example: NPH 20 units AM, 12 units PM → NPH 8 units Suhoor, 16 units Iftar

Evidence: The Treat4Ramadan study comparing degludec with glargine U-100 showed 75% reduction in hypoglycemia with degludec during Ramadan[10].

Clinical Pearl: The "reverse titration" approach—start with larger dose reduction (30%) in first week of Ramadan, then uptitrate by 2-4 units every 3 days based on fasting glucose patterns. This "start low, go slow" strategy prevents early hypoglycemia while achieving optimization.

Oyster to Remember: The "Suhoor insulin timing paradox"—administering basal insulin too close to end of Suhoor meal (within 30 minutes of dawn) increases mid-day hypoglycemia risk. Optimal timing is 60-90 minutes before dawn, requiring patients to wake earlier.

Clinical Hack: Use continuous glucose monitoring (CGM) or flash glucose monitoring in high-risk patients during the first week of Ramadan to identify hypoglycemia patterns. The Ramadan Prospective Diabetes Study showed CGM reduced hypoglycemia by 40%[11].

Premixed Insulin: Complex but Manageable

Premixed insulins (70/30, 75/25, 50/50) combine basal and prandial components, requiring careful redistribution.

Recommended Approach:

Preferred strategy: Switch to basal-bolus regimen 4-6 weeks before Ramadan for better flexibility
If continuation necessary:
- Give larger dose (60-70% of total) with Iftar
- Give smaller dose (30-40% of total) with Suhoor
- Reduce total daily dose by 20-30%

Example:

Before Ramadan: 30 units before breakfast, 20 units before dinner
During Ramadan: 15 units Suhoor, 30 units Iftar

Clinical Pearl: The "Iftar spike phenomenon"—traditional Iftar begins with dates and sweet beverages, causing rapid glucose excursion. Instruct patients to administer premixed insulin 15-20 minutes before Iftar (during Maghrib prayer time) and begin Iftar with protein or salad before consuming dates.

Basal-Bolus Regimen: The Gold Standard for Type 1 Diabetes

Basal-bolus therapy offers maximum flexibility but requires sophisticated self-management.

Recommended Adjustment:

Basal Insulin:

Reduce by 20-30% overall
Consider split-dose regimen: 40% with Suhoor, 60% with Iftar for degludec/glargine U-300
For glargine U-100/detemir: maintain twice-daily dosing

Bolus Insulin:

Discontinue or minimize (10-20% of usual) with Suhoor
Give 40-50% of total daily bolus dose with Iftar
Distribute remaining doses with post-Taraweeh (evening prayer) snack and late-night meal if applicable
Teach carbohydrate counting and insulin:carb ratios for variable meal sizes

Evidence: The DiaRamadan study showed that 75% of type 1 diabetes patients completing structured education successfully completed Ramadan with basal-bolus therapy[12].

Clinical Hack: The "three-meal Ramadan strategy" for type 1 diabetes:

Suhoor: Small bolus dose (2-4 units) with complex carbohydrates
Iftar: Main bolus dose (40-50% of total daily) with traditional meal
Late meal (10-11 PM): Moderate bolus with snack to prevent nocturnal hypoglycemia

Advanced Technique: For insulin pump users, create two custom basal rate patterns:

Fasting pattern: Reduce basal rates by 20-40% during daytime (6 AM-6 PM), maintain evening rates
Non-fasting pattern: Standard rates for non-fasting days Activate fasting pattern each morning during Ramadan

Oyster: The "nocturnal nadir phenomenon"—patients often experience lowest glucose levels at 2-4 AM during Ramadan, not mid-afternoon as expected. This occurs because late-night meals are often carbohydrate-light, while Iftar insulin doses remain elevated. Consider 10-20% reduction in Iftar bolus if late-night meal is modest.

Glucose Monitoring: The Safety Net

Self-Monitoring Blood Glucose (SMBG) Recommendations

Minimum Testing Frequency:

Type 1 or insulin-treated type 2: 4-6 times daily (pre-Suhoor, mid-morning, mid-afternoon, pre-Iftar, 2-hour post-Iftar, before bed)
Non-insulin therapy: 2-3 times daily (mid-afternoon, pre-Iftar, post-Iftar)

Critical Testing Times:

Mid-afternoon (2-4 PM): Highest hypoglycemia risk
Pre-Iftar: Guides Iftar meal size and medication
2 hours post-Iftar: Identifies hyperglycemic excursions
Before sleep: Prevents nocturnal hypoglycemia

Clinical Pearl: SMBG does not break the fast according to major Islamic scholarly consensus (Fatwa). Emphasize this to overcome patient reluctance.

Continuous Glucose Monitoring: The Game-Changer

CGM (Dexcom, Freestyle Libre, Guardian) provides invaluable real-time data and trend arrows during Ramadan.

Advantages:

Identifies asymptomatic hypoglycemia
Trend arrows guide insulin dosing
Alerts prevent severe hypoglycemia
Retrospective data optimizes regimen

Clinical Hack: Set CGM alert thresholds conservatively during Ramadan:

Low alert: 80 mg/dL (4.4 mmol/L) instead of standard 70 mg/dL
High alert: 200 mg/dL (11.1 mmol/L)
Rate-of-change alerts: -2 mg/dL/min for rapid decline

Oyster: The "sensor artifact error"—dehydration during prolonged fasting can affect interstitial fluid glucose measurement, causing falsely low readings. If CGM shows hypoglycemia but patient feels well, confirm with capillary blood glucose before breaking fast.

Breaking the Fast: Clear Thresholds

Patients must understand non-negotiable thresholds for breaking the fast.

Absolute Indications to Break Fast:

Blood glucose <70 mg/dL (3.9 mmol/L)
Blood glucose <90 mg/dL (5.0 mmol/L) with hypoglycemic symptoms
Blood glucose >300 mg/dL (16.7 mmol/L)
Acute illness, vomiting, diarrhea
Presyncope, syncope, altered mental status

Initial Treatment:

15 grams fast-acting carbohydrate (3-4 glucose tablets, 120 mL fruit juice, 3 dates)
Recheck glucose in 15 minutes
Repeat if <70 mg/dL
Consume mixed meal once glucose normalizes

Clinical Hack: Provide patients with "fast-breaking permission card" signed by physician and endorsed by local Islamic scholar, stating medical necessity. This reduces psychological distress and guilt.

The Pre-Ramadan Consultation: Setting Up Success

Structure the pre-Ramadan visit (6-8 weeks before) systematically:

Assessment Components

Risk stratification using DAR categories
Medication review and adjustment plan
Complication screening (retinopathy, neuropathy, nephropathy, cardiovascular disease)
Hypoglycemia history in preceding 3 months
Social factors (occupation, fasting hours, access to medical care)

Education Priorities

Hypoglycemia recognition and treatment
When to break fast (specific glucose thresholds)
Medication timing with written schedule
SMBG technique and frequency
Dietary guidance (see below)
Physical activity modification
Sick day management

Clinical Pearl: Use the "teach-back method"—ask patients to explain back to you when they will take medications, when to break fast, and how to treat hypoglycemia. This identifies knowledge gaps better than asking "Do you understand?"

Dietary Considerations: The Often-Forgotten Component

Suhoor Recommendations

Timing: As late as possible before dawn
Composition: Complex carbohydrates (whole grains, oats), protein (eggs, dairy), healthy fats (nuts, seeds)
Avoid: Simple sugars, high-glycemic foods that cause rapid glucose spike then crash
Hydration: Minimum 500 mL water

Clinical Hack: The "low glycemic Suhoor plate": 1/2 plate non-starchy vegetables, 1/4 plate lean protein, 1/4 plate whole grain, 1 serving healthy fat. This combination provides sustained glucose release.

Iftar Recommendations

Begin with: Dates (1-3) and water (traditional and provides quick energy)
Then: Perform Maghrib prayer (delays rapid eating)
Main meal: Balanced plate with emphasis on protein and fiber
Avoid: Fried foods, excessive sweets, large portions
Spacing: Distribute food over 2-3 hours rather than one large meal

Oyster: The "Iftar rebound hyperglycemia"—patients often overcompensate for daytime fasting with excessive food intake at Iftar, causing marked hyperglycemia. Counsel that Iftar should be similar in size to a regular dinner, not a feast.

Physical Activity: The Delicate Balance

General Recommendations

Reduce intensity during fasting hours (perform at 60-70% usual intensity)
Optimal timing: 1-2 hours after Iftar when glucose and hydration are replete
Avoid: Intense exercise in late afternoon or evening before Iftar
Taraweeh prayers: Count as light-moderate activity, may require small snack afterward

Clinical Pearl: For patients who habitually exercise, perform baseline exercise testing before Ramadan to establish safe heart rate ranges during fasting vs. fed states.

Special Populations

Chronic Kidney Disease

CKD 3: Reduce sulfonylureas by 50%, avoid long-acting agents; continue metformin if eGFR >45
CKD 4-5: Avoid fasting; if insisted, use only insulin with 40-50% dose reduction and daily medical supervision

Elderly Patients

Higher hypoglycemia risk due to reduced counter-regulatory response
Simplify regimens: prefer once-daily agents
Involve family members in glucose monitoring and medication administration
Consider more lenient glucose targets (fasting <140 mg/dL, random <180 mg/dL)

Ramadan During Pregnancy (Gestational or Pre-existing Diabetes)

Strong recommendation against fasting due to fetal risk
If patient insists: insulin therapy only, intensive monitoring (6-8 times daily), weekly clinic visits
Lower thresholds for breaking fast (<80 mg/dL or >140 mg/dL)

Emerging Therapies and Future Directions

Automated Insulin Delivery (AID) Systems

Hybrid closed-loop systems (Medtronic 780G, Tandem Control-IQ, Omnipod 5) show promise for Ramadan management. Small studies suggest:

60% reduction in hypoglycemia
Improved time-in-range
Reduced patient burden

Approach: Increase glucose target during fasting hours (130-140 mg/dL instead of 110-120 mg/dL) and reduce insulin sensitivity factor by 20%.

Smart Insulin Pens

Connected insulin pens (InPen, NovoPen 6) provide dose tracking and reminders—valuable when medication schedules shift.

Tirzepatide: Dual GIP/GLP-1 Agonist

Early data suggest tirzepatide may offer advantages over GLP-1 agonists alone during Ramadan with minimal hypoglycemia risk, though specific Ramadan studies are pending.

Common Clinical Scenarios: Practical Solutions

Scenario 1: Patient on Metformin + Glimepiride Arrives 2 Weeks Before Ramadan

Approach:

Discontinue glimepiride immediately
Start DPP-4 inhibitor (e.g., sitagliptin 100 mg daily)
Continue metformin 1000 mg with Iftar, 500 mg with Suhoor
Provide glucose meter, teach SMBG
Schedule follow-up call after 1 week of fasting

Scenario 2: Type 1 Diabetes on Glargine 24 Units Daily + Lispro 8-10-8 Units

Approach:

Switch glargine to Iftar timing, reduce to 18 units
Lispro: 2 units Suhoor, 12 units Iftar, 6 units late meal (10 PM)
Initiate CGM if possible
SMBG: before Suhoor, 10 AM, 3 PM, before Iftar, 2 hours post-Iftar, bedtime
Contact clinic immediately if glucose <70 or >300 mg/dL twice

Scenario 3: Type 2 Diabetes on Premixed 30/70 Insulin 30-0-20 Units

Approach:

Week before Ramadan: Switch to basal-bolus (glargine 20 units + lispro 8-8-8)
During Ramadan: Glargine 16 units with Iftar, lispro 2-10-6 units
Alternative if patient refuses change: 30/70 15 units Suhoor, 30 units Iftar
Intense counseling about Iftar timing and dietary control

Pearls and Oysters: Summary

Pearls:

Start planning 6-8 weeks early, not days before Ramadan
Risk stratification guides intensity of intervention
DPP-4 inhibitors and GLP-1 agonistsare safest medication classes
Reduce, don't just redistributeinsulin and sulfonylureas
CGM is transformative for high-risk patients
Education prevents complicationsmore than medication adjustment alone
Cultural sensitivity and religious knowledge improve compliance
Suhoor timing matters more than Iftar timing for preventing hypoglycemia

Oysters (Counterintuitive Truths):

Sulfonylureas at Suhoor increase afternoon hypoglycemia (give at Iftar instead)
Nocturnal hypoglycemia is often worse than daytime (reduce Iftar insulin)
Dates at Iftar can cause rebound hypoglycemia in insulin users if insulin timed incorrectly
SMBG does not break the fast(religious misconception to address)
Fasting may improve glycemic control in well-managed patients due to weight loss and dietary discipline
More medications doesn't mean more safety (simplification often reduces risk)

Conclusion

Successful diabetes management during Ramadan requires individualized risk assessment, proactive medication adjustment, intensive patient education, and close monitoring. The availability of newer glucose-lowering agents with minimal hypoglycemia risk (DPP-4 inhibitors, GLP-1 agonists, SGLT2 inhibitors) and advanced monitoring technologies (CGM, connected devices) has dramatically improved safety compared to two decades ago.

The fundamental principle remains: prevention of hypoglycemia takes precedence over perfect glycemic control during Ramadan. A pragmatic approach accepting slightly higher glucose targets (fasting 90-130 mg/dL, post-prandial <180 mg/dL) for one month is preferable to aggressive management risking severe hypoglycemia.

As clinicians, our role extends beyond medical management to cultural competence and collaborative decision-making that respects patients' religious practices while prioritizing their health and safety. The intersection of faith and medicine, when navigated thoughtfully, can strengthen the therapeutic relationship and improve outcomes.

References

Hassanein M, Al-Arouj M, Hamdy O, et al. Diabetes and Ramadan: Practical guidelines. Diabetes Res Clin Pract. 2017;126:303-316.
Salti I, Bénard E, Detournay B, et al. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care. 2004;27(10):2306-2311.
Cahill GF Jr. Fuel metabolism in starvation. Annu Rev Nutr. 2006;26:1-22.
Hassanein M, Akif Buyukbese M, Malek R, et al. Real-world safety and effectiveness of insulin glargine 300 U/mL in participants with type 2 diabetes who fast during Ramadan: The observational ORION study. Diabetes Res Clin Pract. 2020;166:108189.
Aravind SR, Ismail SB, Balamurugan R, et al. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a pragmatic randomized controlled trial. Curr Med Res Opin. 2012;28(8):1289-1296.
Hassanein M, Hanif W, Malik W, et al. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VIRTUE study. Curr Med Res Opin. 2011;27(7):1367-1374.
Devendra D, Gohel B, Bravis V, et al. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan. Int J Clin Pract. 2009;63(10):1446-1450.
Shao Y, Lim GJ, Chua CL, et al. The effect of Ramadan fasting and continuing sodium-glucose co-transporter-2 (SGLT2) inhibitor use on ketonemia, blood pressure and renal function in Muslim patients with type 2 diabetes. Diabetes Res Clin Pract. 2018;142:85-91.
Brady EM, Davies MJ, Gray LJ, et al. A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial. Diabetes Obes Metab. 2014;16(6):527-536.
Hassanein M, Buyukbese MA, Malek R, et al. Real-world safety and effectiveness of insulin degludec in participants with type 1 diabetes fasting during Ramadan: The prospective, observational DIA-RAMADAN study. Diabetes Res Clin Pract. 2019;151:324-331.
Beshyah SA, Hassanein M, Ahmedani MY, et al. Diabetic hypoglycaemia during Ramadan fasting: a trans-national observational real-world study. Diabetes Res Clin Pract. 2019;150:315-321.
Ahmedani MY, Alvi SF, Haque MS, et al. Implementation of Ramadan-focused diabetes education, patient assessments and structured monitoring (RaDIANT) and its impact in diabetic subjects during Ramadan. Pak J Med Sci. 2015;31(2):289-293.

Conflict of Interest: None declared

Acknowledgments: The author thanks the countless patients who have shared their Ramadan experiences and taught invaluable clinical lessons that cannot be found in textbooks.

Word Count: 3,147 words